Ceftolozane Synthesis via Convergent 7-ACA Coupling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing ceftolozane, an antibacterial agent, face challenges with low yields and the need for extensive purification steps, making them unsuitable for industrial-scale production.
Innovation Solution
A convergent method using 7-aminocephalosporanic acid (7-ACA) as the starting material, where the pyrazole moiety is introduced followed by the thiadiazole moiety, with a one-pot procedure for alkylation and amide coupling, and the use of orthogonal protecting groups for efficient purification and deprotection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional methods are used to synthesize ceftolozane with multiple protection and purification steps, then the product purity can be achieved, but the production yield is low and the process is complex
Solution Approach 1:
The synthesis is divided into modular stages: (i) coupling pyrazole side chain to 7-ACA, (ii) coupling thiadiazole side chain to the intermediate, and (iii) global deprotection. Each stage uses orthogonal protecting groups that can be selectively removed, allowing independent optimization of each step while maintaining overall high yield and purity.
Solution Approach 2:
The patent employs specific parameter optimizations including: using DIC/DMAP catalysis for amide couplings to improve efficiency, selecting TFA/anisole for global deprotection to achieve high yields, and optimizing solvent systems for crystallization to enhance purity without requiring extensive purification steps.
2Manufacturing precision
If extensive purification steps are performed to obtain pure ceftolozane, then the product quality is improved, but the number of process steps and time consumption increase
Solution Approach 1:
The synthesis design allows intermediates and final product to crystallize in high purity forms directly from the reaction mixtures or after simple filtration, eliminating the need for complex purification steps. The orthogonal protecting group strategy ensures that deprotection steps do not generate difficult-to-remove impurities.
Solution Approach 2:
The patent utilizes crystallization as a primary purification method at key stages: crystallization of the pyrazole-coupled intermediate, crystallization of the thiadiazole-coupled intermediate, and final crystallization of ceftolozane. These phase transitions efficiently separate product from impurities without requiring chromatographic or extensive filtration steps.
3Productivity
If a convergent synthesis approach is used to reduce purification steps, then the productivity is improved, but the manufacturing complexity increases
Solution Approach 1:
The convergent synthesis is segmented into two main coupling sequences: pyrazole attachment followed by thiadiazole attachment (or vice versa), with each sequence being independently manageable. This segmentation allows the complexity to be distributed across standardized, repeatable modules rather than requiring management of a single complex pathway.
Solution Approach 2:
Orthogonal protecting groups serve as intermediaries that temporarily mask functional groups during specific coupling steps. These protecting groups (e.g., Boc, Cbz, Fmoc, Trt) can be selectively installed and removed without affecting other parts of the molecule, simplifying the management of synthesis complexity while enabling convergent pathways.
4Reliability
If multiple protection groups are used to enable selective coupling, then the selectivity is improved, but the number of deprotection steps and overall process time increase
Solution Approach 1:
Protecting groups are strategically installed before coupling steps to prevent unwanted reactions. For example, the amino group of 7-ACA is protected with Boc or Cbz before pyrazole coupling, and the carboxylic acid is protected as methyl or benzyl ester. These preliminary protection steps enable high selectivity in subsequent couplings while allowing for efficient global deprotection later.
Solution Approach 2:
Instead of removing protecting groups after each coupling step, the patent employs global deprotection strategies where all protecting groups are removed in a single final step (or few steps) after all couplings are complete. This inversion of the traditional approach reduces the number of deprotection-coupling cycles and significantly shortens overall process time.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in higher yields with fewer purification steps, making the process more efficient and scalable for industrial production while reducing material costs and waste.
Implementation Method 1
reacting a compound of formula II with a silylating agent
Implementation Method 2
and with iodotrimethylsilane
Implementation Method 3
reacting the products of steps a-i) and a-ii)
Implementation Method 4
in the presence of a base
Implementation Method 5
The reaction mixture was concentrated
Implementation Method 6
afforded the title compound after filtration
Data Source
AI summary
The present invention relates to a highly convergent method for the synthesis and purification of ceftolozane and intermediates starting from 7-aminocephaiosporanic acid (7- ACA).